Did you mean?
Search Results - Showing 36 - 48 Of 120
_ruth-m-oregan-md-and-debu-tripathy-md-on-hr-her2-breast-cancer-results-from-the-monaleesa-7-trial.webp "Ruth M. O’Regan, MD, of the University of Wisconsin Carbone Cancer Center, and Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer.")
⏲ 2 min 73 sec ✓ 07-Dec-2017
_cytonics-developing-the-cure-for-osteoarthritis-through-novel-protein-engineering.webp "Cytonics® is a biotechnology company specializing in the development of diagnostics and therapeutics for osteoarthritis (OA), a disease of the joints that renders the afflicted immobile and in constant pain. Our technology leverages the therapeutic potential of a blood protein called Alpha-2-macroglobulin (A2M), which is able to bind to and inhibit the catabolize enzymes that degrade cartilage tissue in arthritic joints. Our first therapy was a medical device that purifies and concentrates A2M")
⏲ 3 min 97 sec ✓ 17-Apr-2022
_prolia-study-from-2015-san-antonio-breast-cancer-symposium.webp "A study presented at the 2015 San Antonio Breast Cancer Symposium has found that Prolia reduced recurrence risk for postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer taking an aromatase inhibitor.")
_zerust-excor-vapor-capsule-corrosion-inhibitor-diffusers.webp "How to use ZERUST®/EXCOR® VCI Vapor Capsules and how the work.")
_ruth-o39regan-md-on-locally-advanced-and-metastaticbreast-cancer-results-of-the-belle-3-trial.webp "Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR+, HER2+, aromatase inhibitor–treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor–based treatment (Abstract S4-07).")
⏲ 2 min 0 sec ✓ 10-Dec-2016
_daf-merck-victrelis.webp "DAf was invited to produce a campaign for Merck USA to launch Victrelis, a protease inhibitor used to treat Hepatitis C. The drug’s key factor is its accuracy in locating and fighting virus replication. With this in mind, we helped focus the campaign on one decisive representation: the precise attack of a fencer. nnUnder the direction of Felipe Dacaret, the production took us to New York, with 2 days of shooting for photo and video. From there, it was back to Chile for the post. nnIn the Liver")
_cortexyme-small-molecule-mechanism-of-action.webp "Cortexyme gingipain inhibitor mechanism of action in Alzheimer's disease")
_patricia-a-ganz-md-on-aromatase-inhibitors-data-review-expert-perspective.webp "Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor-associated musculoskeletal symptoms, and aromatase inhibitor’s effect on endothelial function and heart disease (Abstracts S5-06 and S5-07).")
⏲ 1 min 93 sec ✓ 10-Dec-2016
_laurence-albiges-md-phd-and-toni-k-choueiri-md-on-rcc-novel-combinations-for-advanced-disease.webp "Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss two treatment studies: one testing pegilodecakin with nivolumab or pembrolizumab and the other evaluating an oral CXCR4 inhibitor in combination with axitinib (Abstracts 4509 & 4510).")
Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on RCC: Novel Combinations for Advanced Disease
⏲ 1 min 71 sec ✓ 03-Jun-2018
_paul-e-goss-md-phd-on-post-menopausal-early-stage-breast-cancer-extending-letrozole-treatment.webp "Paul E. Goss, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, discusses disease-free survival results from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA1).")
⏲ 2 min 57 sec ✓ 05-Jun-2016
_cyanopeptolin-1020-binding-to-bovine-trypsin.webp "Toxic cyanobacteria are responsible for many poisonings of livestock, animals and even humans when drinking contaminated freshwater. In collaboration with scientists from the University of Zürich, we have recently isolated a second class of toxins exemplified by cyanopeptolin 1020 from the cyanobacterium Microcystis. In addition, we have shown that cyanopeptolin 1020 is a very potent and “dirty” protease inhibitor thus leading to rapid death of the crustacean T. platyurus. nnKarl Gademann,")
_julie-lemieux-md-on-letrozole-in-post-menopausal-early-stage-breast-cancer-patient-reported-outcomes.webp "Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506).")
⏲ 1 min 79 sec ✓ 05-Jun-2016
![[+]](/images/menu.gif){kind=small}